High dose magnesium sulfate exposure induces apoptotic cell death in the developing neonatal mouse brain

Neonatology

Volumn 96, Issue 1, 2009, Pages 23-32

  Dribben, William H ^a   Creeley, Catherine E ^a   Wang, Hai Hui ^a   Smith, Derek J ^a   Farber, Nuri B ^a   Olney, John W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase 3; Magnesium sulfate; Neurodevelopment; Pre eclampsia; Preterm labor

Indexed keywords

CASPASE 3; MAGNESIUM SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; CAUDATE NUCLEUS; CELL DEATH; CELL KILLING; CEREBELLUM; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; ELECTRON MICROSCOPY; EXPERIMENTAL MOUSE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL DIFFERENTIATION; NEUROTOXICITY; NEWBORN; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; SILVER STAINING;

AGING; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BRAIN; CASPASE 3; CEREBRAL CORTEX; COPPER; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MAGNESIUM SULFATE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; NEURONS; SILVER; STAINING AND LABELING; THALAMUS;

ANIMALIA; MUS;

EID: 59549084173     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000201327     Document Type: Article

References (54)

1. Martin JN, Thigpen BD, Moore RC, Rose CH, Cushman J, May W:Stroke and severe preeclampsia and eclampsia:a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005;105:246-254.
2. Mittendorf R, Pryde P, Khoshnood B, Lee KS:If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? Obstet Gynecol 1998;92:308-311.
3. Grimes DA, Nanda K:Magesium sulfate to- colysis:time to quit. Obstet Gynecol 2006;108:986-989.
4. Sibai BM:Magnesium sulfate is the ideal anticonvulsant in preeclampsia-eclampsia. Am J Obstet Gynecol 1990;163:1141-1145.
5. Gathwala G, Khera A, Singh I:Magnesium therapy in birth asphyxia. Indian J Pediatr 2006;73:209-212.
6. Ichiba H, Yokoi T, Tamai H, Ueda T, Kim TJ, Yamano T:Neurodevelopmental outcome of infants with birth asphyxia treated with magnesium sulfate. Pediatr Int 2006;48:7075.
7. Perlman JM:Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clin Ther 2006;9:1353-1365.
8. Wiswell TE, Graziani LJ, Kornhauser MS, Stanley C, Metron DA, Mckee L, Spitzer AR:Effects of hypocarbia on the development of cystic periventricular leukomalacia in premature infants treated with high-frequency jet ventilation. Pediatrics 1996;98:918-924.
9. Nelson KB, Grether JK:Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:263-269.
10. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P:Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low- birth weight children aged 3 to 5 years. JAMA 1996;276:1805-1810.
11. Kuban KC, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M:Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J Child Neurol 1992;7:70-76.
12. Perlman JM, Rollins NK, Evan D:Neonatal stroke:Clinical characteristics and cerebral blood flow velocity measurements. Pediatr Neurol 1994;11:281-284.
13. FineSmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, Kahn A, Fish I:Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in pre- term infants. Am J Perinatol 1997;14:303-307.
14. Nassar AH, Usta IM:Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor:a randomized controlled trail. Obstet Gynecol 2007;110:1170-1171.
15. Nassar AH, Salti I, Makarem NN, Usta IM:Marked hypocalcemia after tocolytic magnesium sulphate therapy. Am J Perinatol 2007;24:481-482.
16. Cox SM, Sherman ML, Leveno KJ:Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990;265:6633-6637.
17. Crowther CA, Hiller JE, Doyle LW:Magnesium sulphate for preventing preterm birth in threatened preterm labor. Cochrane Database Syst Rev 2002;4:CD001060.
18. Lyell DJ, Pullen K, Campbell L, Ching S,Druzin ML, Chikara U, Burrs D, Caughey AB, El-Sayed YY:Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor:a randomized controlled trial. Obstet Gynecol 2007;110:61-67.
19. Doyle LW, Crowther CA, Middleton P, Marret S:Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2007;CD004661.
20. Leviton A, Paneth N, Susser M, Reuss ML, Allred EN, Kuban K, Sanocka U, Hegyi T, Hiatt M, Shahrivar F, Van Marter LJ:Maternal receipt of magnesium sulfate does not seem to reduce the risk of neonatal white matter damage. Pediatrics 1997;99:E2.
21. Marret S, Doyle LW, Crowther CA, Middleton P:Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007;12:311-317.
22. Paneth N, Jetton J, Pinto-Martin J, Susser M:Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis Group. Pediatrics 1997;99:E1.
23. Canterino JC, Verma UL, Visintainer PF, Figueroa R, Klein SA, Tejani NA:Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Obstet Gyne-col 1999;99:396-402.
24. Kimberlin DF, Hauth JC, Goldenberg RL,Bottoms SF, Iams JD, Mercer B, MacPherson C, Thurnau GR:The effect of maternal magnesium sulfate treatment on neonatal morbidity in
25. Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, Lusky A, Bental Y:Effect of maternal tocolysis on the incidence of severe periventricular/in- traventricular haemorrhage in very low birthweights infants. Arch Dis Child Fetal Neonatal Ed 2001;85:F13-F17.
26. Boyle CA, Yeargin-Allsopp M, Schendel DE, Holmgreen P, Oakley GP:Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less thatn 1,750 grams. Am J Epidemiol 2000;152:120-124.
27. Doyle LW, Crowther CA, Middleton P, Marret S:Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2007;CD004661.
28. Crowther CA, Hiller JE, Doyle LW:Magnesium sulphate for preventing preterm birth in threatened preterm labor. Cochrane Database Syst Rev 2002:CD001060.
29. Mittendorf R, Pryde PG:A review of the role of magnesium sulphate in preterm labour.BJOG 2005;1:84-88.
30. Fomin VP, Gibbs SG, Vanam R, Morimiya A, Hurd WW:Effect of magnesium sulfate on contractile force and intracellular calcium concentration in pregnant human myome- trium. Am J Obstet Gynecol 2006;194:1384-1390.
31. Cunze T, Rath W, Osmers R, Martin M,Warneke G, Kuhn W:Magnesium and calcium concentration in the pregnant and non-pregnant myometrium. Int J Gynaecol Obstet 1995;48:9-13.
32. Lemancewicz A, Laudanska H, Laudanski T, Karpiuk A, Batra S:Permeability of fetal membranes to calcium and magnesium:possible role in preterm labour. Hum Reprod 2000;15:2018-2022.
33. Mizuki J, Taska K, Masumoto N, Kasahara K, Miyake A, Tanizawa O:Magnesium sul- fate inhibits oxytocin-induced calcium mobilization in human puerperal myometrial cells:possible involvement of intracellular free magnesium concentration. Am J Obstet Gynecol 1993;169:134-139.
34. Fredriksson A, Archer T, Alm H, Gordh T, Eriksson P:Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav Brain Res 2004;153:367-376.
35. Fredriksson A, Archer T:Neurobehavioural deficits associated with apoptotic neurode- generation and vulnerability for ADHD.Neurotox Res 2004;6:435-456.
36. Fredriksson A, Ponten E, Gordh T, Eriksson P:Neonatal exposure of a combination of N-methyl-D-aspartate and gamma-aminobu- tyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. Anesthe- siology 2007;107:427-436.
37. Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF:Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 2003;23:876-882.
38. Dobbing J, Sands J:Comparative aspects of the brain growth spurt. Early Hum Dev 1979;3:79-83.
39. Rice D, Barone S:Critical periods of vulnerability for the developing nervous system:evidence from human and animal models.Environ Health Perspect 2000;108S3:535544.
40. Mittendorf R, Stratford R, Khoshnood B, Lee KS, Pryde P:Persistence of elevated serum magnesium levels in the neonate. Am J Ob-stet Gynecol 2001;134:S50.
41. Mittendorf R, Dammann O, Lee KS:Brain lesions in newborns exposed to high-dose magnesium sulfate during preterm labor. JPerinatol 2006;26:57-63.
42. DeOlmos J, Ebbesson S, Heimer L:Silver methods for the impregnation of degenerating axoplasm;in Heimer L, Robards N (eds):Neuroanatomical Tract-Tracing Methods. New York, Plenum, 1990, pp 117-168.
43. Young C, Tenkova T, Dikranian K, Olney JW:Excitotoxic versus apoptotic mechanisms of neuronal cell death in perinatal hyp- oxia/ischemia. Curr Mol Med 2004;4:7785.
44. Gundersen HJ, Bagger P, Bendtsen TF, et al:The new stereological tools:dissector, frac- tionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988;96:857-881.
45. West MJ, Slomainka L, Gundersen HJ:Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fraction- ator. Anat Rec 1991;231:482-497.
46. Pryde PG, Borg MJ, Mittendorf R, Elin RJ:Cord-blood ionized magnesium (iMg) levels exceed maternal levels in both untreated and tocolytic magnesium sulfate treated preterm neonates. Am J Obstet Gynecol 1999;180:S106.
47. Witlin AG:Prevention and treatment of eclamptic convulsions. Clin Obstet Gynecol 1999;42:507-518.
48. Dikranian K, Ishimaru MJ, Tenkova T, La-bruyere J, Qin YQ, Ikonomidou C, Olney JW:Apoptosis in the in vivo mammalian fore- brain. Neurobiol Dis 2001;8:359-379.
49. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefo-vska V, Turski L, Olney JW:Blockade of NMDA receptors and apoptotic neurode- generation in the developing brain. Science 1999;283:70-74.
50. MittendorfR, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M:Is tocolytic magnesium sulphate associated with increased total pae- diatric mortality. Lancet 1997;350:1517-1518.
51. Mittendorf R, Dambrosia, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, Tomich PG:Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Ob-stet Gynecol 2002;186:1111-1118.
52. Crowther CA, Hiller JE, Doyle LW, Haslam RR:Effect of magnesium sulfate given for neuroprotection before preterm birth:a randomized controlled trial. JAMA 2003;290:2669-2676.
53. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Leveque C, Hellot MF, Benichou J:Magnesium sulphate given before very-pre-term birth to protect infant brain:the randomized controlled PREMAG trial. BJOG 2007;114:310-318.
54. Marret S, Marpeau L, Follet-Bouhamad C, Cambonie G, Astruc D, Delaporte B, Bruel H, Guillois D, Pinquier D, Zupan-Simunek V, Benichou J:Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn with two year neurological outcome:results of the prospective PREMAG trial. Gynécologie Obstétrique &Fertilité2008;36:278- 288